Recognition of ¥222 million in R&D expenses
First written in FY2019-Q3. . Latest entry: FY2026.
- FY2026Research and development expenses increased to ¥406 millionAnnual report
「Total R&D expenses of the Group for the current consolidated fiscal year were ¥406 million.」
R&D expenses increased from ¥358 million in the previous fiscal year to ¥406 million. In the healthcare business, the Company is investing in a tablet-component inspection system and next-generation models of image processing units. - FY2026-H1R&D expenses increased to ¥203 millionAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥203 million.」
Total R&D expenses increased from ¥180 million in the same period of the previous year to ¥203 million. - FY2025-H1R&D expenses decreased to ¥180 millionAnnual report
「Total R&D expenses for the current interim consolidated accounting period were ¥180 million.」
Total R&D expenses decreased from ¥228 million in the same period of the previous year to ¥180 million. - FY2024R&D expenses decreased to ¥358 millionAnnual report
「Total R&D expenses of the Group for the current consolidated fiscal year were ¥358 million.」
R&D expenses decreased from ¥372 million in the previous fiscal year to ¥358 million, while the healthcare business continued developing AI inspection functions, strategic equipment for overseas markets and image processing for electronic components. - FY2024-Q3R&D expenses decreased to ¥244 millionAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥244 million.」
Total R&D expenses decreased from ¥266 million in the same period of the previous year to ¥244 million. - FY2024-Q2R&D expenses decreased to ¥158 millionAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥158 million.」
Total R&D expenses decreased from ¥228 million in the same period of the previous year to ¥158 million. - FY2024-Q1R&D expenses decreased to ¥75 millionAnnual report
「Total R&D expenses for the cumulative first quarter of the current consolidated fiscal year were ¥75 million.」
Total R&D expenses were ¥75 million, a slight decrease from ¥76 million in the same period of the previous year. - FY2023R&D expenses decreased to ¥372 millionAnnual report
「Total R&D expenses of the Group for the current consolidated fiscal year were ¥372 million.」
R&D expenses decreased from ¥397 million in the previous fiscal year to ¥372 million, while the healthcare business advanced the development of AI image processing and inspection equipment for overseas markets. - FY2023-Q3R&D expenses changed to ¥266 millionAnnual report
「Total R&D expenses for the cumulative third quarter of the current consolidated fiscal year were ¥266 million.」
Total R&D expenses were ¥266 million, down from ¥280 million in the same period of the previous year but up from ¥228 million in the cumulative previous quarter. - FY2023-Q2R&D expenses increased to ¥228 millionAnnual report
「Total R&D expenses for the cumulative second quarter of the current consolidated fiscal year were ¥228 million.」
Total R&D expenses increased from ¥190 million in the same period of the previous year to ¥228 million. - FY2023-Q1Research and development expenses increased to ¥86 millionAnnual report
「Total research and development expenses for the three months ended the first quarter amounted to ¥86 million.」
Total R&D expenses increased from ¥76 million in the same period of the previous year to ¥86 million. - FY2022-Q3Research and development expenses increased to ¥280 millionAnnual report
「Total research and development expenses for the nine months ended the third quarter amounted to ¥280 million.」
Total research and development expenses increased from ¥231 million in the same period of the previous year to ¥280 million. - FY2022-Q2Research and development expenses increased to ¥190 millionAnnual report
「Total research and development expenses for the six months ended the second quarter amounted to ¥190 million.」
Total research and development expenses increased from ¥150 million in the same period of the previous year to ¥190 million. - FY2022-Q1Research and development expenses increased to ¥76 millionAnnual report
「Total research and development expenses for the three months ended the first quarter amounted to ¥76 million.」
Total research and development expenses increased from ¥60 million in the same period of the previous year to ¥76 million. - FY2021Research and development expenses increased to ¥384 millionAnnual report
「Total research and development expenses of the Group for the current consolidated fiscal year amounted to ¥384 million.」
Total research and development expenses increased from ¥329 million in the previous fiscal year to ¥384 million. - FY2021-Q3Research and development expenses increased to ¥270 millionAnnual report
「Total research and development expenses for the nine months ended the third quarter amounted to ¥270 million.」
Total research and development expenses increased from ¥231 million in the same period of the previous year to ¥270 million. - FY2021-Q2Research and development expenses increased to ¥177 millionAnnual report
「Total research and development expenses for the six months ended the second quarter amounted to ¥177 million.」
Total research and development expenses increased from ¥150 million in the same period of the previous year to ¥177 million. - FY2021-Q1Research and development expenses increased to ¥76 millionAnnual report
「Total research and development expenses for the three months ended the first quarter amounted to ¥76 million.」
Total research and development expenses amounted to ¥76 million, up from ¥60 million in the same period of the previous year. - FY2020-Q3Research and development expenses increased to ¥231 millionAnnual report
「Total research and development expenses for the nine months ended the third quarter amounted to ¥231 million.」
Total research and development expenses increased from ¥222 million in the same period of the previous year to ¥231 million. - FY2020-Q2Research and development expenses increased to ¥150 millionAnnual report
「Total research and development expenses for the six months ended the second quarter amounted to ¥150 million.」
Total research and development expenses amounted to ¥150 million in the six months ended the second quarter, changing from ¥222 million in the nine months ended the third quarter of the previous fiscal year and ¥60 million in the three months ended the first quarter of the current fiscal year. - FY2020-Q1Research and development expenses decreased to ¥60 millionAnnual report
「Total research and development expenses for the three months ended the first quarter amounted to ¥60 million.」
Total research and development expenses amounted to ¥60 million, down from ¥222 million in the nine months ended the third quarter of the previous fiscal year. - FY2019-Q3First statedAnnual report
「Total research and development expenses for the nine months ended the third quarter amounted to ¥222 million.」
Total research and development expenses of ¥222 million for the nine months ended the third quarter were disclosed.